Mirum Pharmaceuticals Inc Earnings

Mirum Pharmaceuticals Inc’s revenue jumped 42.93% since last year same period to $99.41Mn in the Q4 2024. On a quarterly growth basis, Mirum Pharmaceuticals Inc has generated 10% jump in its revenue since last 3-months.

Mirum Pharmaceuticals Inc’s net profit jumped 28.23% since last year same period to $-23.79Mn in the Q4 2024. On a quarterly growth basis, Mirum Pharmaceuticals Inc has generated -67.12% fall in its net profits since last 3-months.

Mirum Pharmaceuticals Inc’s net profit margin jumped 49.79% since last year same period to -23.93% in the Q4 2024. On a quarterly growth basis, Mirum Pharmaceuticals Inc has generated -51.93% fall in its net profit margins since last 3-months.

Mirum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a -94.65% fall from last quarter’s estimates.

Mirum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.48.

Mirum Pharmaceuticals Inc’s earning per share (EPS) jumped 25.76% since last year same period to -0.49 in the Q4 2024. This indicates that the Mirum Pharmaceuticals Inc has generated 25.76% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mirum Pharmaceuticals Inc’s return on assets (ROA) stands at -0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mirum Pharmaceuticals Inc’s return on equity (ROE) stands at -0.37.